8-K filings / November 13, 2026
Acurx Pharmaceuticals, Inc.: A change of officers or directors
Acurx Pharmaceuticals, Inc. filed a current report (Form 8-K) with the SEC on November 13, 2026. It reports a change of officers or directors.
AI-written from the facts below
In plain English
Joseph C. Scodari is leaving the board of directors, effective November 13, 2026. This board change is reported under Item 5.02 of Form 8-K, the section covering directors and senior officers who leave or are appointed.
What each sentence states
“Joseph C. Scodari is leaving the board of directors, effective November 13, 2026.”
- Item 5.02: Joseph C. Scodari leaves the board of directors, effective November 13, 2026.
“This board change is reported under Item 5.02 of Form 8-K, the section covering directors and senior officers who leave or are appointed.”
- Item 5.02 of Form 8-K covers directors and senior officers who leave or are appointed.
- Item 5.02: Joseph C. Scodari leaves the board of directors, effective November 13, 2026.
Item 5.02
Officers and directors
-
Leaves
Joseph C. Scodari, DirectorEffective November 13, 2026
From the filing
Source
“On November 12, 2026, Joseph C. Scodari, a member of the Board of Directors (the “Board”) of Acurx Pharmaceuticals, Inc. (the “Company”) since 2021, provided the Company with notice of his intention to retire from the Board, effective November 13, 2026.”
Read by code from this sentence of the filing.
Not investment advice.Read the filing on SEC.gov
Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.